Advanced Biomed Inc. Common Stock (ADVB)vsDanaher Corporation (DHR)
ADVB
Advanced Biomed Inc. Common Stock
$7.78
-5.01%
HEALTHCARE · Cap: $14.62M
DHR
Danaher Corporation
$203.23
+1.55%
HEALTHCARE · Cap: $140.97B
Smart Verdict
WallStSmart Research — data-driven comparison
DHR leads profitability with a 16.0% profit margin vs 0.0%. ADVB trades at a lower P/E of 2.1x. DHR earns a higher WallStSmart Score of 66/100 (B-).
ADVB
Avoid33
out of 100
Grade: F
DHR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADVB.
Margin of Safety
-68.9%
Fair Value
$118.49
Current Price
$203.23
$84.74 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADVB
The strongest argument for ADVB centers on P/E Ratio, Price/Book, Debt/Equity.
Bull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 19.8%. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bear Case : ADVB
The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Key Dynamics to Monitor
ADVB profiles as a value stock while DHR is a mature play — different risk/reward profiles.
DHR is growing revenue faster at 5.5% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (66/100 vs 33/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Advanced Biomed Inc. Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?